Paliperidone and pharmacokinetics
Common Questions and Answers about Paliperidone and pharmacokinetics
invega
60 mg divided dose? how and when? Does it mean in 2 parts/3/4/? parts? Can it be morning=20mg, lunch=20mg, dinner=20 mg? Please tell me the definition of divided dose with an example.
Q2: How I can determine how often to administer a drug based on pharmacokinetics? For example it says:
- Absorption, oral: time to peak concentration 7h
- Elimination half-life = 12 h
(It says also that in general it can be administered once daily because it has a 24 h effect.Why?
Finally, since about year he began giving him INVEGA (paliperidone) injection 50 mg which he is fine with it.
The problem is that he has become sperm non-existent as he told me.
Will it disappear in case he stop taking the injection after a long period of use???? I am very confused, particularly as he wants to get married and be a father.
About a month ago I was able to lower my self off of paliperidone and onto ziprasidone which is the same category of drug as paliperidone but studies have shown that out of all antipsychotics ziprasidone had the least amount of weight gain. So I’ve been on ziprasidone for about a month now and I’m still losing weight while walking. Sometimes after my walks I only accumulate around 100 calories a day. On days that I splurge a bit and take in around 800 calories a day, I gain weight though.
The products in question are Temodar (temozolomide) for brain cancer and hepatitis C and cancer drugs PegIntron (pegylated interferon alfa-2b) and Intron A (interferon alfa-2b), according to Merck's just-published quarterly report. All three of the drugs were acquired when Merck bought Schering-Plough in 2009.
Ribavirin is widely distributed in all tissues, including the CSF and brain. The pharmacokinetics of ribavirin is dominated by trapping of the phosphate form inside cells, particularly red blood cells (RBCs) which lack the enzyme to remove the phosphate once it has been added by kinases, and therefore attain high concentrations of the drug. Most of the kinase activity which converts the drug to active nucleotide form, is provided by adenine kinase.
I have had a chronic pattern of elevated wbc and neutrophils for 5 months now but only slightly elevated over those 5 months, however symptoms have increased and having extreme lethargy, night sweats and now daytime sweats and weakness. Most recent labs now show higher WBC 21 (range 4.5-11)and neutrophils 78 range (42-75) and low lymphocytes 13 (range 20-51). My doctor has me on 10mg of prednisone but he doesn’t feel the prednisone would increase my labs that much. Please help.
Hepatic Impairment
In volunteers with hepatic impairment (Child-Pugh Class A and B), sildenafil clearance was reduced, resulting in higher plasma exposure of sildenafil (47% for Cmax and 85% for AUC). The pharmacokinetics of sildenafil in patients with severely impaired hepatic function (Child-Pugh Class C) have not been studied. A starting dose of 25 mg should be considered in patients with any degree of hepatic impairment [see Dosage and Administration (2.5) and Clinical Pharmacology (12.3)].
Folic acid supplementation in folate-deficient patients with epilepsy changes the pharmacokinetics of phenytoin, usually leading to lower serum phenytoin concentrations and possible seizure breakthrough..."
It however says that initiation of Folic acid and phenytoin together is beneficial.
Since you can't go back and start all over again, you can take a small dose. It has been observed that as los as 1mg dose can perturb phenytoin’s levels, You may take doses lower than 1mg/day.
The Phase 1 trial was designed to characterize the safety profile of ARC-520 across a range of doses and evaluate pharmacokinetics. It is a single-center, randomized, double-blind, placebo-controlled, single dose-escalation, first-in-human study of ARC-520 administered intravenously to healthy adult volunteers. All subjects have been dosed and received either placebo or ARC-520 in doses ranging from 0.01 mg/kg to 2 mg/kg.
i believe in the pre-clinical trials with healthy volunteers, researchers used Carbon14 to gauge the half-life and paths of elimination during pharmacokinetics studies. it is a common practice. perhaps that is what you are thinking about?
I took Wellbutrin for 20 years, and ended up with drug induced lupus, I know I am very very rare, but I don't know about cirhosis ?
Do you have to take an antidepressant , maybe diet, exercise, and once you are cured with new oral treatments allot of the depression goes away, I promise you that
I take nothing now and am doing very very good
When do you start treatment ?
7 Hepatic Impairment
No dosage adjustment is required in patients with mild to moderate hepatic impairment. The safety and pharmacokinetics in patients with severe hepatic impairment have not been evaluated [see Clinical Pharmacology (12.3)].
gov
Rank Status Study 1 Recruiting
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection
Condition: Hepatitis C, Chronic
Intervention: Drug: GS-6620
4 Recruiting
A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
Condition: Chronic Hepatitis C Infection
Intervent
Recommended
